Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a OVX836 dose-ranging influenza vaccine study in healthy adults and older adults
2021-002535-39Phase 2Completed
- Sponsor
- Osivax
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OVX836 in influenza (4 arms), sponsored by Osivax. Primary endpoint: Co-primary endpoints. Started Sep 2021; status: completed.
02
Drugs
OVX836
03
Conditions
influenza
Beyond the preview
Go deeper on 2021-002535-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002535-39.